论文部分内容阅读
目的:在临床证实肾系康治疗系膜增生性肾炎血尿具有明显疗效基础上,试图通过系膜增生性肾炎动物模型验证其疗效,并明确各不同拆方亚组的作用强弱及协同,以指导临床应用。方法:用刘震报道的方法加以改进建立大鼠MsPGN模型,并检测各组大鼠尿液中红细胞数以判定治疗结果。结果:肾系康及滋阴、活血组能够减少MsPGN大鼠尿红细胞数。结论:肾系康对MsPGN血尿有显著疗效,方中滋阴活血药起主要作用,临床治疗血尿可加大用量。
OBJECTIVE: To verify the efficacy of Shenjiukang in the treatment of mesenteric proliferative nephritis with hematuria, and to try to verify the efficacy of the mesangial proliferative nephritis animal model, and to determine the strengths and weaknesses of various disassembled subgroups and synergy. Guide clinical application. Methods: The rat MsPGN model was established by using the method reported by Liu Zhen. The number of red blood cells in the urine of each group was determined to determine the treatment outcome. RESULTS: The Kidney-Yikang, Nourishing yin, and Huoxue groups were able to reduce the number of urinary red blood cells in MsPGN rats. Conclusion: Shenkangkang has a significant effect on MsPGN hematuria, Fangzhongzhongyin Huoxue drugs play a major role, and hematuria can be increased in clinical treatment.